Selective PPAR δ Activation and Seladelpar Efficacy in Primary Biliary Cholangitis and beyond

Alessio Gerussi; Matteo Fornai

doi:10.1016/j.phrs.2026.108144

February 1, 2026Pharmacological ResearchOpen Access

Selective PPAR δ Activation and Seladelpar Efficacy in Primary Biliary Cholangitis and beyond

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to review the role of Seladelpar as a PPAR-δ agonist in treating Primary Biliary Cholangitis.
Reviewed characteristics of PPAR-δ across different tissues.
Summarized the pharmacology of Seladelpar.
Discussed clinical efficacy and safety in humans.
Seladelpar is effective in patients not responding to first-line therapy.
Examination of its safety profile reveals manageable side effects.

Implication

This review outlines the efficacy of Seladelpar for cholestatic disease, highlighting its pharmacology and clinical safety.

Abstract

Seladelpar is a selective PPAR-δ agonist approved for the treatment of the rare cholestatic disease Primary Biliary Cholangitis, in patients who do not achieve adequate biochemical control with first-line therapy. This review outlines the characteristics of PPAR-δ, with insights into its activity across different tissues, and summarizes the pharmacology of Seladelpar, providing the background for the subsequent discussion of its clinical efficacy and safety in humans.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gerussi et al. (2026) studied this question.

synapsesocial.com/papers/69994ad4873532290d01f324 https://doi.org/10.1016/j.phrs.2026.108144

View Full Paper

Ask AI

Bookmark

Share

Selective PPAR δ Activation and Seladelpar Efficacy in Primary Biliary Cholangitis and beyond

Key Points

Implication

Abstract

Discussion

Cite This Study

Selective PPAR δ Activation and Seladelpar Efficacy in Primary Biliary Cholangitis and beyond

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading